By
Ask a regulatory affairs lead at a mid-market biotech what keeps them up at night, and the answer rarely involves a single agency or a single rule. It's the overlap. FDA quality system updates, EMA data expectations, and a new wave of EU AI Act obligations are landing in the same fiscal year, often touching the same systems, and most organizations are still tracking them in a patchwork of spreadsheets, legacy CRM instances, and validated-but-siloed point solutions.
Regulatory compliance in life sciences has always meant more paperwork than most industries tolerate. What's changed is the pace. Where a compliance calendar once had a handful of fixed dates, life sciences teams now manage a rolling set of framework updates that arrive faster than most quality systems were designed to absorb. A platform that can't keep audit trails, consent records, and content approvals current in real time turns every inspection into a scramble.
This is where Salesforce has made a deliberate push into the industry with Life Sciences Cloud and Agentforce Life Sciences, purpose-built tools meant to close the gap between how fast regulations change and how fast a life sciences organization can actually respond. The rest of this post breaks down where regulatory compliance in life sciences stands heading into the back half of 2026, how Salesforce addresses the specific pressure points, and what it actually takes to get a validated, compliant implementation live.
The state of regulatory compliance in life sciences in 2026
Three regulatory tracks are converging on life sciences organizations at once, and none of them are optional. In the US, the Quality Management System Regulation took effect in February 2026, aligning FDA device quality requirements with ISO 13485 and requiring documentation practices many manufacturers haven't fully implemented. The FDA's first draft guidance on Form 483 response requirements, published in March 2026, raised the bar again for how inspection findings get addressed and recorded. Meanwhile, the EU AI Act's high-risk classification for certain life sciences applications is on track to finalize in August 2026, and the Digital Omnibus has pushed the compliance deadline for AI in medical devices and IVDs to August 2028, an acknowledgment of just how complex layering AI Act conformity on top of existing MDR and IVDR pathways has become.
Layered on top of the framework changes is a data problem. Regulators increasingly expect real-world evidence, not just clinical trial data, to support safety and efficacy claims, and that evidence has to come with a documented chain of provenance. Data governance has effectively become a compliance requirement in its own right, not a back-office IT concern.
What this looks like in practice for most organizations:
- Fragmented systems of record. Clinical, medical, and commercial data often live in separate platforms with no unified audit trail, making it hard to demonstrate consistent oversight across a product's lifecycle.
- Manual MLR review cycles. Medical, legal, and regulatory approval for commercial and patient-facing content is still largely manual at many organizations, which slows time-to-market and increases the risk of an outdated or non-compliant asset slipping through.
- AI governance gaps. As AI tools move from pilot to production in drug discovery, pharmacovigilance, and regulatory intelligence, few organizations have documented explainability, bias monitoring, or version control sufficient to satisfy AI Act-style requirements.
- Reactive audit prep. Many teams still reconstruct audit trails after the fact rather than maintaining them continuously, which turns every inspection into a fire drill instead of a formality.
None of this means the regulatory bar is unreasonable. It means the systems most life sciences organizations built five or ten years ago were never designed for this level of cross-framework, real-time scrutiny.
How Salesforce solves these challenges
1. A unified, audit-ready data foundation
Salesforce Life Sciences Cloud starts from a single data model spanning clinical, medical, and commercial functions, which directly addresses the fragmented-systems problem described above. Instead of stitching together audit evidence from three or four disconnected platforms after the fact, compliance and quality teams work from one system of record with a continuously maintained audit trail.
This matters because GxP-adjacent compliance isn't really a feature you buy. It's a property of how a validated process actually gets implemented, and that only holds up if the underlying data model doesn't force teams to reconcile records across systems every time an auditor asks a question. Salesforce Shield adds field-level audit trails and encryption on top of that foundation, giving quality teams the kind of granular change history that regulators expect during inspection.
For organizations migrating off a legacy CRM (Veeva included), this is often the single biggest source of project risk. Data migration with intact audit trails, integration rebuilds, and validation of regulated flows like sampling and adverse event intake routing typically take far longer than the CRM configuration itself. Getting the data foundation right up front prevents a compliant go-live from becoming a compliance liability six months later.
2. Automated MLR and regulated content management
Manual medical, legal, and regulatory review is one of the slowest, most error-prone parts of life sciences operations, and it's a direct target for Salesforce's regulated content management capabilities within Agentforce Life Sciences. Version control, agentic MLR review, and secure distribution work together to help ensure that everything from a patient-facing website to a rep-facing brochure is scientifically accurate and has cleared the right approval chain before it goes live.
The AI layer here is doing enforcement work, not just automation for speed. Agentforce is grounded in Salesforce's Trust Layer and runs on Hyperforce infrastructure, which is built to help organizations meet HIPAA, GxP, and GDPR requirements simultaneously rather than satisfying one framework at the expense of another.
Practically, this shortens the gap between content creation and compliant publication, and it gives regulatory teams a defensible, timestamped record of every review and approval decision. That record is exactly what an inspector or auditor asks for first.
- Version-controlled content libraries across commercial, medical, and clinical teams
- AI-assisted MLR routing with full approval history
- Secure, permissioned distribution to HCPs and patients
3. Data governance built for real-world evidence
As regulators lean more heavily on real-world evidence from electronic health records, registries, and claims data, life sciences organizations need a way to govern that data with the same rigor they've historically applied to clinical trial data. Salesforce's data platform, paired with Life Sciences Cloud, is built to connect and govern data from disparate sources while maintaining the documentation of provenance regulators now expect.
This isn't a cosmetic capability. Regulatory intelligence tools increasingly need to trace exactly where a data point came from, how it was transformed, and who touched it, especially when that data supports a safety or efficacy claim in a submission. A governed, unified data layer turns that traceability into something the system produces automatically rather than something a team assembles under deadline pressure.
Combined with consent management tools built into the platform, organizations get a defensible answer to two of the hardest questions regulators ask: where did this data come from, and did the patient consent to how it's being used.
4. AI governance with built-in explainability
The EU AI Act's high-risk classification for certain life sciences AI applications, and the FDA and EMA's joint guiding principles on good AI practice in drug development, both point to the same requirement: organizations need explainability, version control, and audit logs for every AI system touching a regulated process. Salesforce's approach to AI governance inside Life Sciences Cloud treats these as native features of the platform rather than bolt-ons.
Agentforce Life Sciences is designed around grounded, auditable outputs rather than opaque model behavior, which matters enormously when a regulator asks why an AI-assisted MLR decision or a pharmacovigilance flag came out the way it did. Organizations that pair this with disciplined change control, including well-documented predetermined change control plans, are better positioned to update AI models iteratively without triggering a new regulatory submission every time.
- Audit logs and version history for AI-assisted decisions
- Change control documentation aligned to FDA and EMA AI guidance
- Continuous monitoring rather than periodic, submission-driven review
Why TELUS Digital
Salesforce ships the compliance infrastructure. Whether that infrastructure actually holds up under inspection depends entirely on how it's implemented, validated, and maintained, and that's where most life sciences Salesforce projects run into trouble. Treating validation of regulated flows, like sampling workflows or adverse event intake, as a side task rather than its own workstream with its own owner is one of the most common ways compliant intent turns into an audit finding.
TELUS Digital brings Salesforce implementation depth to life sciences organizations who need more than a standard CRM rollout. Our teams pair AI & Data expertise with Agentforce configuration experience across healthcare and life sciences environments, so validation and audit-readiness are built into the project plan from day one rather than retrofitted after go-live. Managed services support keeps that compliance posture current as regulations, and Salesforce's own product roadmap, continue to shift, and our enterprise quality practice brings the testing rigor regulated environments require.
If regulatory compliance in life sciences is currently a reactive scramble at your organization rather than a continuous, validated process, talk to our team about what a Salesforce implementation built for audit-readiness actually looks like.
